These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 25096586

  • 1. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
    Niewerth M, Minden K, Klotsche J, Horneff G.
    Z Rheumatol; 2014 Aug; 73(6):532-40. PubMed ID: 25096586
    [Abstract] [Full Text] [Related]

  • 2. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].
    Minden K, Klotsche J, Niewerth M, Horneff G, Zink A.
    Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365
    [Abstract] [Full Text] [Related]

  • 3. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
    Yamazaki S, Shimbo A, Akutsu Y, Takase H, Morio T, Mori M.
    Pediatr Rheumatol Online J; 2020 Mar 23; 18(1):26. PubMed ID: 32293465
    [Abstract] [Full Text] [Related]

  • 4. Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBO.
    Vollbach K, Tenbrock K, Wagner N, Horneff G, Klein A, Foeldvari I, Haas JP, Aries P, Gauler G, Striesow F, Hoff P, Scholz C, Tatsis S, Seipelt E, Klotsche J, Minden K.
    Arthritis Res Ther; 2022 Dec 13; 24(1):271. PubMed ID: 36514116
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies.
    Vidqvist KL, Malin M, Varjolahti-Lehtinen T, Korpela MM.
    Rheumatology (Oxford); 2013 Nov 13; 52(11):1999-2003. PubMed ID: 23893666
    [Abstract] [Full Text] [Related]

  • 7. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y, Schanberg LE, Tomlinson GA, Riordan ME, Dennos AC, Del Gaizo V, Murphy KL, Weiss PF, Natter MD, Feldman BM, Ringold S, CARRA STOP-JIA Investigators.
    Arthritis Rheumatol; 2021 Oct 13; 73(10):1898-1909. PubMed ID: 34105312
    [Abstract] [Full Text] [Related]

  • 8. Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients.
    Mannion ML, Xie F, Baddley J, Chen L, Curtis JR, Saag K, Zhang J, Beukelman T.
    Pediatr Rheumatol Online J; 2016 Sep 05; 14(1):49. PubMed ID: 27596158
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
    Arthritis Rheumatol; 2014 Sep 05; 66(9):2580-9. PubMed ID: 24942886
    [Abstract] [Full Text] [Related]

  • 10. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
    McErlane F, Foster HE, Davies R, Lunt M, Watson KD, Symmons DP, Hyrich KL.
    Rheumatology (Oxford); 2013 Oct 05; 52(10):1905-13. PubMed ID: 23873820
    [Abstract] [Full Text] [Related]

  • 11. Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries.
    Kearsley-Fleet L, Klotsche J, van Straalen JW, Costello W, D'Angelo G, Giancane G, Horneff G, Klein A, Láday M, Lunt M, de Roock S, Ruperto N, Schoemaker C, Vijatov-Djuric G, Vojinovic J, Vougiouka O, Wulffraat NM, UK JIA Biologics Registers Investigators Group; Paediatric Rheumatology International Trials Organisation (PRINTO), Hyrich KL, Minden K, Swart JF.
    Rheumatology (Oxford); 2022 May 30; 61(6):2524-2534. PubMed ID: 34613385
    [Abstract] [Full Text] [Related]

  • 12. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, Panaviene V, Bader-Meunier B, Anton J, Nielsen S, De Benedetti F, Kamphuis S, Staņēviča V, Tracahana M, Ailioaie LM, Tsitsami E, Klein A, Minden K, Foeldvari I, Haas JP, Klotsche J, Horne AC, Consolaro A, Bovis F, Bagnasco F, Pistorio A, Martini A, Wulffraat N, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry.
    Arthritis Res Ther; 2018 Dec 27; 20(1):285. PubMed ID: 30587248
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry.
    Drechsel P, Stüdemann K, Niewerth M, Horneff G, Fischer-Betz R, Seipelt E, Spähtling-Mestekemper S, Aries P, Zink A, Klotsche J, Minden K.
    Rheumatology (Oxford); 2020 Mar 01; 59(3):603-612. PubMed ID: 31412128
    [Abstract] [Full Text] [Related]

  • 15. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R, Carrasco R, Foster HE, Baildam EM, Chieng SEA, Davidson JE, Ioannou Y, Wedderburn LR, Thomson W, Hyrich KL.
    Semin Arthritis Rheum; 2016 Oct 01; 46(2):190-195. PubMed ID: 27422803
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R, Balfe LM, Greene L.
    J Manag Care Pharm; 2012 Oct 01; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [Abstract] [Full Text] [Related]

  • 18. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
    Becker I, Horneff G.
    Arthritis Care Res (Hoboken); 2017 Apr 01; 69(4):552-560. PubMed ID: 27390133
    [Abstract] [Full Text] [Related]

  • 19. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2015 Jul 01; 74(7):1379-86. PubMed ID: 24641940
    [Abstract] [Full Text] [Related]

  • 20. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.
    Khawaja K, Al-Maini M.
    Pediatr Rheumatol Online J; 2017 May 16; 15(1):41. PubMed ID: 28511684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.